The Chinese oncology market is increasingly important to both multinational and local pharmaceutical companies. However, access to high-cost medicines is fragmented within China. This study explored current prescribing and reimbursement of high-cost, targeted cancer therapies for gastric cancer (GC) and hepatocellular carcinoma (HCC).
METHODS
Seventy-six oncologists from different tier cities in China (Table 1) were surveyed regarding their current and expected future prescribing practices for the treatment of GC and HCC. In addition, 3 payers who influence reimbursement at national and/or regional levels were interviewed.
RESULTS
Reimbursement is considered the greatest barrier to accessing targeted therapies.
• Chemotherapy still dominates GC and HCC treatment in China, with only 20% of patients receiving targeted therapy.
• No targeted therapies for GC and HCC are on the National Reimbursement Drug List (NRDL), although some agents are included on the Provincial reimbursement Drug Lists (PRDLs) ( Table 2 ).
• Almost 60% of HCC patients do not receive sorafenib due to cost/ reimbursement-related reasons (Figure 1 ).
• Payers report that it will be very difficult for high-cost targeted therapies to be included on the NRDL, although they are increasingly likely to be included in the PRDLs. The greatest problem is that the drugs are too expensive. 
CONCLUSION
Pharmaceutical companies have a huge opportunity for their high-cost cancer therapies in China.
• Patient assistance programs and private insurance schemes, along with government initiatives such as negotiation for selective provincial formularies inclusion and "catastrophic diseases" coverage will help break the market access barrier.
An uneven healthcare environment between cities means local market access strategies will be needed to guarantee the greatest patient share.
• Tier 2/3 cities have much less access to high-cost therapies and therefore offer the greatest market opportunity. Local strategies need to be developed for targeting Tier 2/3 cities if market penetration is to be maximized.
Strategies to break down the barriers to targeted treatment.
• Striking a bargain:
» A new policy initiative allows inclusion of expensive drugs in individual PRDLs via a bargaining system between the provincial government and manufacturers.
• Patient access programs (PAPs):
» PAPs are set up by pharmaceutical companies in collaboration with the China Charity Federation or Cancer Foundation of China to help patients who cannot afford to pay out-of-pocket expenses. Such programs include Roche's PAP for trastuzumab and Bayer's PAP for sorafenib.
• Improved medical insurance:
» Coverage for "catastrophic diseases" has been implemented in around 120 cities in China, which makes it possible for expensive drugs to be reimbursed under this new initiative.
There is disparity in access to cancer therapies between different tier cities.
• More patients in Tier 1 cities have urban resident basic medical insurance than in Tier 2/3 cities (34% versus 24%).
• In Tier 1 cities, relatively more patients receive targeted therapy (23% versus 16%), compared with Tier 2/3 cities (Figure 2 ).
• The cost of these therapies is lower in Tier 1 cities than in most Tier 2/3 cities (trastuzumab costs $1800 per cycle in Shanghai versus $2500 in Shijiazhuang) (Figure 3 ). 
